drugset / Trial / NCT00002157
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
Completed
Celgene Corporation
Open-labelTreatment
Summary
To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting in order to support Celgene's pivotal placebo-controlled study.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | — | — |